Back

Angiotensin converting enzyme 2 activity predicts outcome in heart failure with preserved ejection fraction

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 6 - Chronic heart failure – pathophysiology and mechanisms Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Premium Access ESC Congress 2018

About the speaker

Photo
Ms Christina Binder

Medical University of Vienna, Vienna (Austria)

14 More presentations in this session

Presentation thumbnail
Appropriate hemoglobin levels in HFpEF patients: results of Japanese heart failure syndrome with preserved ejection fraction (JASPER) registry
Doctor K. Okuno (Philadelphia, US)
Abstract
Presentation thumbnail
Impact of left ventricular pressure overload on relaxation and stiffness in patients with preserved ejection fraction: noninvasive study using speckle tracking echocardiography
Doctor S. Minatoguchi (Gifu, JP)
Abstract
Presentation thumbnail
Cyclic guanosine monophosphate enhancing therapeutic strategy for heart failure with preserved ejection fraction (cGETS study): effects on cardiac dysfunction and remodeling.
Doctor E. Dal Canto (Utrecht, NL)
Abstract Slides
Presentation thumbnail
Renin activity is an independent predictor of outcome in patients with heart failure and preserved ejection fraction independent of RAAS blocker therapy
Ms C. Binder (Vienna, AT)
Abstract
Presentation thumbnail
Extracellular volume fraction measured by cardiac magnetic resonance imaging can help to evaluate left ventricular stiffness noninvasively by representing histological collagen volume fraction
Doctor T. Omori (Tsu , Mie, JP)
Abstract

Access the full session

Session thumbnail
Poster Session 6 - Chronic heart failure – pathophysiology and mechanisms

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Presentation
Pharmacotherapy in HFpEF: where do cardiometabolic drugs fit in?
thumbnail
Congress Session
Clinical phenotypes of heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources